Should I buy or sell Humacyte stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HUMA shares. View HUMA analyst ratings or view top-rated stocks .

What is Humacyte's stock price target for 2024?

3 brokerages have issued 12-month price objectives for Humacyte's shares. Their HUMA share price targets range from $3.00 to $16.00. On average, they anticipate the company's stock price to reach $7.75 in the next year. This suggests a possible upside of 191.4% from the stock's current price. View analysts price targets for HUMA or view top-rated stocks among Wall Street analysts .

How have HUMA shares performed in 2023?

Humacyte's stock was trading at $2.11 at the start of the year. Since then, HUMA stock has increased by 26.1% and is now trading at $2.66. View the best growth stocks for 2023 here .

Are investors shorting Humacyte?

Humacyte saw a increase in short interest in November. As of November 15th, there was short interest totaling 6,090,000 shares, an increase of 10.7% from the October 31st total of 5,500,000 shares. Based on an average daily volume of 583,200 shares, the short-interest ratio is currently 10.4 days. Currently, 8.1% of the shares of the stock are short sold. View Humacyte's Short Interest .

When is Humacyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024. View our HUMA earnings forecast .

How were Humacyte's earnings last quarter?

Humacyte, Inc. (NASDAQ:HUMA) posted its earnings results on Thursday, November, 9th. The company reported ($0.25) EPS for the quarter, hitting analysts' consensus estimates of ($0.25).

What ETFs hold Humacyte's stock?

ETFs with the largest weight of Humacyte (NASDAQ:HUMA) stock in their portfolio include Clough Select Equity ETF (CBSE) . Clough Long/Short Equity ETF (CBLS) .

Who are Humacyte's major shareholders?

Humacyte's stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.50%), Charles Schwab Investment Management Inc. (0.44%), GSA Capital Partners LLP (0.34%), LPL Financial LLC (0.33%), Rokos Capital Management LLP (0.19%) and United Asset Strategies Inc. (0.14%). Insiders that own company stock include Brady W Dougan , Dale A Sander, Heather Ledbetter Prichard, Laura E Niklason , Michael T Constantino and William John Scheessele. View institutional ownership trends .

How do I buy shares of Humacyte?

Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Humacyte Stock Price, News & Analysis (NASDAQ:HUMA)

$2.66

+0.01 (+0.38%)

(As of 12/1/2023 ET)

Compare

Today's Range: $2.59
▼
$2.84
50-Day Range: $1.99
▼
$2.96
52-Week Range: $1.96
▼
$5.60

Volume: 851,573 shs
Average Volume: 449,501 shs
Market Capitalization: $275.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.75

Humacyte MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 191.4% Upside
$7.75 Price Target
Short Interest: Bearish
8.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.29
Based on 2 Articles This Week
Insider Trading: Selling Shares
$5.56 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.94) to ($0.96) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars

Medical Sector

832nd out of 954 stocks

Biological Products, Except Diagnostic Industry

145th out of 159 stocks

3.3

Analyst's Opinion

Consensus Rating
Humacyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.75, Humacyte has a forecasted upside of 191.4% from its current price of $2.66.
Amount of Analyst Coverage
Humacyte has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.13% of the float of Humacyte has been sold short.
Short Interest Ratio / Days to Cover
Humacyte has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Humacyte has recently increased by 10.73%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Humacyte does not currently pay a dividend.
Dividend Growth
Humacyte does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HUMA.

2.4

News and Social Media Coverage

News Sentiment
Humacyte has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Humacyte this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for HUMA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
3 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Humacyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,560,000.00 in company stock.
Percentage Held by Insiders
23.10% of the stock of Humacyte is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 27.36% of the stock of Humacyte is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Humacyte are expected to decrease in the coming year, from ($0.94) to ($0.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Humacyte is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Humacyte is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Humacyte has a P/B Ratio of 7.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Humacyte Stock (NASDAQ:HUMA)

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

HUMA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HUMA Stock News Headlines

November 24, 2023 | finance.yahoo.com

Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023 | seekingalpha.com

Humacyte: Upcoming BLA, Pivotal Data, Decent Cash, Excellent Opportunity

December 1, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 18, 2023 | markets.businessinsider.com

Promising Clinical Trials and Innovative Technology Bolster Buy Rating for Humacyte Stock

November 17, 2023 | finance.yahoo.com

Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma

November 14, 2023 | theglobeandmail.com

Instrument Name Humacyte Inc Instrument Symbol (HUMA-Q)

November 11, 2023 | markets.businessinsider.com

Promising Outlook for Humacyte: Buy Rating Highlighted by Strong Pipeline Progress and Financial Stability

November 10, 2023 | finance.yahoo.com

Q3 2023 Humacyte Inc Earnings Call

December 1, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

November 10, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Century Therapeutics (IPSC), Humacyte (HUMA)

November 10, 2023 | finanznachrichten.de

Humacyte, Inc: Humacyte Third Quarter 2023 Financial Results and Business Update

November 9, 2023 | benzinga.com

Humacyte: Q3 Earnings Insights

November 9, 2023 | msn.com

Humacyte GAAP EPS of -$0.25 in-line

November 9, 2023 | finance.yahoo.com

Humacyte Third Quarter 2023 Financial Results and Business Update

November 8, 2023 | msn.com

Humacyte Q3 2023 Earnings Preview

November 8, 2023 | benzinga.com

Humacyte's Earnings: A Preview

November 2, 2023 | finance.yahoo.com

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023

October 16, 2023 | finance.yahoo.com

Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model

October 2, 2023 | finance.yahoo.com

Several Insiders Invested In Humacyte Flagging Positive News

September 21, 2023 | msn.com

Cantor Fitzgerald Reiterates Humacyte (HUMA) Overweight Recommendation

September 21, 2023 | finance.yahoo.com

Humacyte to Present at the Cantor Global Healthcare Conference

September 18, 2023 | finance.yahoo.com

Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023

September 12, 2023 | finance.yahoo.com

Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma

September 11, 2023 | marketwatch.com

Stocks to Watch: Oracle, Acelyrin, Humacyte

September 11, 2023 | finance.yahoo.com

Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET

August 22, 2023 | msn.com

Humacyte: Major Catalysts Ahead, Solid Prospects, Low Prices

August 21, 2023 | msn.com

Alleged Russian crime boss sanctioned by Ukraine owns a major stake in US biotech firm

See More Headlines

Receive HUMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HUMA
CUSIP: N/A
CIK: 1818382
Web: www.constellationalpha.com
Phone: 919-313-9633
Fax: N/A
Employees: 164
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.75
High Stock Price Target: $16.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +191.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.87)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,970,000.00
Net Margins: N/A
Pretax Margin: -286,051.63%
Return on Equity: -124.36%
Return on Assets: -52.40%

Debt

Debt-to-Equity Ratio: 0.46
Current Ratio: 6.79
Quick Ratio: 6.79

Sales & Book Value

Annual Sales: $1.57 million
Price / Sales: 175.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.36 per share
Price / Book: 7.39

Miscellaneous

Outstanding Shares: 103,570,000
Free Float: 79,649,000
Market Cap: $275.50 million
Optionable: Optionable
Beta: 1.22

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Laura E. Niklason M.D. (Age 60)
Ph.D., Founder, President, CEO & Director
Comp: $717.85k
Mr. Dale A. Sander (Age 63)
CFO, Chief Corporate Development Officer & Treasurer
Comp: $667.45k
Dr. Shamik J. Parikh M.D. (Age 50)
Chief Medical Officer
Comp: $514.72k
Dr. Juliana L. Blum Ph.D.
Co-Founder & Executive Advisor
Dr. Heather Ledbetter Prichard Ph.D. (Age 45)
Chief Operating Officer
Comp: $576.44k
Ms. Sabrina Osborne
Executive Vice President of Business Strategy & People
Mr. William John Scheessele (Age 51)
Chief Commercial Officer
Mr. Harold Alterson
Senior Vice President of Quality
Dr. Yang Cao M.D. (Age 57)
Ph.D., Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HUMA Stock Analysis - Frequently Asked Questions

Should I buy or sell Humacyte stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HUMA shares.
View HUMA analyst ratings or view top-rated stocks.
What is Humacyte's stock price target for 2024?: 3 brokerages have issued 12-month price objectives for Humacyte's shares. Their HUMA share price targets range from $3.00 to $16.00. On average, they anticipate the company's stock price to reach $7.75 in the next year. This suggests a possible upside of 191.4% from the stock's current price.
View analysts price targets for HUMA or view top-rated stocks among Wall Street analysts.
How have HUMA shares performed in 2023?: Humacyte's stock was trading at $2.11 at the start of the year. Since then, HUMA stock has increased by 26.1% and is now trading at $2.66.
View the best growth stocks for 2023 here.
Are investors shorting Humacyte?: Humacyte saw a increase in short interest in November. As of November 15th, there was short interest totaling 6,090,000 shares, an increase of 10.7% from the October 31st total of 5,500,000 shares. Based on an average daily volume of 583,200 shares, the short-interest ratio is currently 10.4 days. Currently, 8.1% of the shares of the stock are short sold.
View Humacyte's Short Interest.
When is Humacyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024.
View our HUMA earnings forecast.

How were Humacyte's earnings last quarter?: Humacyte, Inc. (NASDAQ:HUMA) posted its earnings results on Thursday, November, 9th. The company reported ($0.25) EPS for the quarter, hitting analysts' consensus estimates of ($0.25).
What ETFs hold Humacyte's stock?: ETFs with the largest weight of Humacyte (NASDAQ:HUMA) stock in their portfolio include Clough Select Equity ETF (CBSE).Clough Long/Short Equity ETF (CBLS).
Who are Humacyte's major shareholders?: Humacyte's stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.50%), Charles Schwab Investment Management Inc. (0.44%), GSA Capital Partners LLP (0.34%), LPL Financial LLC (0.33%), Rokos Capital Management LLP (0.19%) and United Asset Strategies Inc. (0.14%). Insiders that own company stock include Brady W Dougan, Dale A Sander, Heather Ledbetter Prichard, Laura E Niklason, Michael T Constantino and William John Scheessele.
View institutional ownership trends.
How do I buy shares of Humacyte?: Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HUMA) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial